A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China

Vaccine

Volumn 31, Issue 50, 2013, Pages 5940-5947

  Li, Rongcheng ^a   Huang, Lirong ^a   Li, Jia ^b   Mo, Zhaojun ^a   He, Bin ^c   Wang, Yunpeng ^b   Wu, Xiaohong ^b   Minutello, Maria ^d   Guinet Morlot, Françoise ^d   Pichon, Sylvie ^d  

^a GUANGXI CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^c Guilin Center for Diseases Control and Prevention   (China)

^d SANOFI PASTEUR   (France)

Author keywords

Clinical trial; Immunogenicity; Post exposure prophylaxis; Rabies; Rabies vaccine; Safety

Indexed keywords

NEUTRALIZING ANTIBODY; RABIES VACCINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CHINA; COMMON COLD; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; PAIN; PHASE 3 CLINICAL TRIAL; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RABIES; RABIES VIRUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHOOL CHILD; SORE THROAT; SWELLING; URTICARIA; VERO CELL;

CLINICAL TRIAL; IMMUNOGENICITY; POST-EXPOSURE PROPHYLAXIS; RABIES; RABIES VACCINE; SAFETY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; CHINA; CULTURE MEDIA, SERUM-FREE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; POST-EXPOSURE PROPHYLAXIS; RABIES; RABIES VACCINES; TECHNOLOGY, PHARMACEUTICAL; VERO CELLS; YOUNG ADULT;

EID: 84887616382     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.043     Document Type: Article

References (8)

1. WHO expert consultation on rabies 2013, WHO, WHO, Geneva, Technical Report Series No. 982. http://apps.who.int/iris/bitstream/10665/85346/1/9789241209823_eng.pdf.
2. Rabies factsheet n°99 2013, WHO, World Health Organization, Geneva. http://www.who.int/mediacentre/factsheets/fs099/en/index.html.
3. Rabies vaccines: WHO position paper - recommendations. Vaccine 2010, 28(44):7140-7142. WHO.
4. Comparability of biotechnological/biological product subject to changes in their manufacturing process. ICH harmonised tripartite guideline. International conference on harmonisation of technical requirements for registration of pharmaceutical for human use 2004, ICH.
5. Pichon S., Guinet-Morlot F., Minutello M., Donazzolo Y., Rouzier R., Chassard D., et al. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab™ for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial. Vaccine 2013, 31(18):2295-2301.
6. Guo Z., Tao X., Yin C., Han N., Yu J., Li H., et al. National borders effectively halt the spread of rabies: the current rabies epidemic in China is dislocated from cases in neighboring countries. PLoS Negl Trop Dis 2013, 7(1):e2039.
7. Measurement method for antibody titers of anti-rabies immune-globulin. In: 2010 Pharmacopoeia of the People's Republic of China, Volume III, Appendices XI and J.
8. Wang L.Y., Sun M.P., Zhang X.C., Suo L.D., Xu R.H., Zou Y.J., et al. Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis. Vaccine 2011 Mar 24, 29(15):2679-2681.